Research progress of selinexor in the treatment of recurrent and refractory multiple myeloma
10.3760/cma.j.cn431274-20230113-00048
- VernacularTitle:塞利尼索治疗复发难治性多发性骨髓瘤的研究进展
- Author:
Heng LIU
1
;
Tao WU
Author Information
1. 中国人民解放军联勤保障部队第九四〇医院血液科/全军血液病中心，兰州 730050
- Keywords:
Multiple myeloma;
Selinexor;
Exportin 1
- From:
Journal of Chinese Physician
2024;26(2):296-300
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma is an incurable hematological malignancy. Although the continuous development of therapeutic drugs such as proteasome inhibitors and immune modulators, as well as chimeric antigen receptor T-cell (CAR-T) therapy, has improved the prognosis in recent years, some patients are still drug-resistant, presenting as refractory and recurrent disease with limited treatment options. Selinexor, a first-in-class oral selective nuclear export protein inhibitor, binds to and inhibits nuclear export protein XPO-1 to function, leading to the accumulation of tumor suppressor proteins in the nucleus and selective apoptosis of cancer cells. It has shown controllable toxicity and good efficacy in the treatment of recurrent and refractory multiple myeloma. This article discusses the anti-tumor mechanism of selinexor, its clinical research progress, and adverse reactions.
